Kelly Stefano Cole, PhD
Lab: BST3 9014
Pittsburgh, PA 15261
- B.S. - Mount Saint Mary's College (1987)
- PhD - University of Pennsylvania (1994)
- Postdoc - University of Pittsburgh
- Associate Professor
- Associate Professor of Medicine, Infectious Diseases Division
- Associate Professor of Molecular Genetics and Biochemistry
- Associate Professor of Infectious Diseases and Microbiology, Graduate School of Public Health
Dr. Kelly Cole is an Associate Professor of Immunology and the Associate Director of the Regional Biocontainment Laboratory at the University of Pittsburgh. Dr. Cole received her PhD in Immunology from the University of Pennsylvania in 1994. She initially came to the University of Pittsburgh as a postdoctoral associate and moved up the ranks to become Associate Professor. Her current research is in the development of animal models for evaluation of vaccines and therapeutics for emerging infections; these include the development of animal models to study vulnerable populations, and include her recent emphasis to develop and validate the pregnant ferret model to identify potential differences in pathogenicity and virulence associated with the increased morbidity and mortality observed during influenza infection of pregnant women. Dr. Cole’s primary responsibility as Associate Director of the RBL is to oversee the daily operations of the large multi-use, multi-pathogen, high-containment facility, and to facilitate projects for internal investigators and external research collaborations. Dr. Cole is nationally recognized for her research in the HIV/SIV vaccine and pathogenesis field for her work on understanding the role of humoral immune responses in experimental infection and vaccination, and has adapted many of these antibody assays for influenza in the RBL. She has published more than 45 peer-reviewed articles, authored several book chapters, serves as a reviewer of many peer-reviewed journals and NIH ad-hoc study sections, and serves on several scientific committees. Dr. Cole has also been instrumental in the biosafety community at the University of Pittsburgh, serving initially on the Biohazards Committee where she helped to develop institutional policy, and, for the last 10 years, serving both as a member and Vice-Chair of the Institutional Biosafety Committee. She was intimately involved in the design, construction/ commissioning and operation of several BSL-3 laboratories, including the RBL, and has become a recognized national scientific expert in the design and operation of high containment laboratories. She currently serves as the Co-Chair of the NIH NBL/RBL Directors and Managers Committee and is an instrumental leader of the Steering Committee for the NBL/RBL Annual Facilities Network Conference.
Cole KS, Smith RE. Successful leadership for a high-containment facility. In: “Management Principles for Building and Operating Biocontainment Facilities: Ten Years of Planning and Management Lessons Learned.” 2013; Tradeline, Inc.; Cole KS, Fisher DJ, Westfall S eds. pp 35-42.
Hartman, AH, Homer LC, Cole KS. Verification of inactivation methods for removal of biological materials from a biosafety level 3 select agent facility. Applied Biosafety 2012; 17:70-75.
Homer LC, Heflin DT, Manning CR, Cole KS. Engineering and work place controls for the use of anesthetic gases during BSL-3 rabbit studies. Applied Biosafety 2011; 16:167-176 (received Richard C. Knudsen Memorial Publication Award).
Reed DS, Smith L, Dunsmore T, Trichel A, Ortiz L, Cole KS, Barry E. Pneumonic tularemia in rabbits resembles the human disease as illustrated by radiographic and hematological changes after infection. PLOS One 2011;.6 (9):e24654.
Kuhrt DM, Faith SA, Leone A, Sodora DL, Picker LK, Borghesi L, Cole KS. Naïve and memory B cells in the rhesus macaque can be differentiated by surface expression of CD27 and have differential responses to CD40 ligation. J Immunol Methods. 2011 Jan 5;363(2):166-76. Epub 2010 Sep 24. PMID:20875419
Faith SA, Wu Y, Kuhrt DM, Steckbeck JD, Craigo JK, Clements JE, Cole KS. Induction of antibody mediated neutralization in SIVmac239 by a naturally acquired V3 mutation. Virology. 2010 Apr 25;400(1):86-92. Epub 2010 Feb 11. PMID:20153009[PubMed - indexed for MEDLINE]
Kuhrt D, Faith SA, Leone A, Rohankedkar M, Sodora DL, Picker LJ, Cole KS. Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population. J Virol. 2010 Mar;84(5):2466-76. Epub 2009 Dec 23. PMID:20032183[PubMed - indexed for MEDLINE] Free PMC Article Kuhrt D,
Faith SA, Leone A, Rohankedkar M, Sodora DL, Picker LJ, Cole KS. Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population. J Virol. 2010 Mar;84(5):2466-76. Epub 2009 Dec 23. PMID:20032183[PubMed - indexed for MEDLINE] Free PMC Article
Cole KS, Fisher DJ, Wesel L. Full Shutdown of Biocontainment Labs is Easier for Recertification: Tradeline Reports 2010; July 7.
Kuhrt DM, Faith SA, Leone A, Picker L, Sodora D, Cole KS. Evidence of early B cell dysregulation in SIV infection: Rapid depletion of naïve and memory B cell subsets with delayed reconstitution of the naïve B cell population. J Virol 2009; 84:2466-2476.
Bright RA, Carter DM, Crevar C, Toapanta FR, Steckbeck JD, Cole KS, Kumar N, Pushko P, Tumpey T, Smith G, Ross TM. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLOS One 2008Jan 30;3(1):e1501.